OBJECTIVE: To investigate whether an elevated interferon-α (IFNα) level early in pregnancy is associated with poor pregnancy outcomes and to examine the relationship of an elevated IFNα level to angiogenic imbalance. METHODS: Women were enrolled in a longitudinal case-control study of pregnant patients with lupus. Serum samples obtained monthly throughout pregnancy were assayed for IFNα and for the antiangiogenic factor soluble Flt-1 and the proangiogenic factor placenta growth factor (PlGF). Each of 28 patients with systemic lupus erythematosus (SLE) with a poor pregnancy outcome was matched to an SLE patient with an uncomplicated pregnancy and to a pregnant healthy control. The effects of IFNα and/or soluble Flt-1 on human endothelial cells and endothelial cell-trophoblast interactions were assessed. RESULTS: Compared to SLE patients with uncomplicated pregnancies, patients with preeclampsia had increased IFNα levels before clinical symptoms. Patients without autoimmune disease who developed preeclampsia did not have increased IFNα levels. In SLE patients with low IFNα levels, marked angiogenic imbalance (higher soluble Flt-1, lower PlGF, and higher soluble Flt-1:PlGF ratios) preceded maternal manifestations of preeclampsia, whereas in SLE patients with high IFNα levels, preeclampsia occurred without evidence of systemic angiogenic imbalance. Treatment of human endothelial cells with soluble Flt-1 induced expression of sFLT1 messenger RNA, and IFNα dramatically amplified responses to soluble Flt-1. In a model of spiral artery transformation, only the combination of IFNα and soluble Flt-1 disrupted the ability of trophoblast cells to remodel endothelial tube structures. CONCLUSION: Our findings identify a new mechanism by which IFNα induces an antiangiogenic milieu and increases the sensitivity of endothelial cells to soluble Flt-1, and suggest that elevated IFNα levels may contribute to the pathogenesis of preeclampsia in some pregnant patients with SLE.
OBJECTIVE: To investigate whether an elevated interferon-α (IFNα) level early in pregnancy is associated with poor pregnancy outcomes and to examine the relationship of an elevated IFNα level to angiogenic imbalance. METHODS:Women were enrolled in a longitudinal case-control study of pregnant patients with lupus. Serum samples obtained monthly throughout pregnancy were assayed for IFNα and for the antiangiogenic factor soluble Flt-1 and the proangiogenic factor placenta growth factor (PlGF). Each of 28 patients with systemic lupus erythematosus (SLE) with a poor pregnancy outcome was matched to an SLEpatient with an uncomplicated pregnancy and to a pregnant healthy control. The effects of IFNα and/or soluble Flt-1 on human endothelial cells and endothelial cell-trophoblast interactions were assessed. RESULTS: Compared to SLEpatients with uncomplicated pregnancies, patients with preeclampsia had increased IFNα levels before clinical symptoms. Patients without autoimmune disease who developed preeclampsia did not have increased IFNα levels. In SLEpatients with low IFNα levels, marked angiogenic imbalance (higher soluble Flt-1, lower PlGF, and higher soluble Flt-1:PlGF ratios) preceded maternal manifestations of preeclampsia, whereas in SLEpatients with high IFNα levels, preeclampsia occurred without evidence of systemic angiogenic imbalance. Treatment of human endothelial cells with soluble Flt-1 induced expression of sFLT1 messenger RNA, and IFNα dramatically amplified responses to soluble Flt-1. In a model of spiral artery transformation, only the combination of IFNα and soluble Flt-1 disrupted the ability of trophoblast cells to remodel endothelial tube structures. CONCLUSION: Our findings identify a new mechanism by which IFNα induces an antiangiogenic milieu and increases the sensitivity of endothelial cells to soluble Flt-1, and suggest that elevated IFNα levels may contribute to the pathogenesis of preeclampsia in some pregnant patients with SLE.
Authors: J P Buyon; K C Kalunian; R Ramsey-Goldman; M A Petri; M D Lockshin; G Ruiz-Irastorza; M Khamashta Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: Kerry McMahon; S Ananth Karumanchi; Isaac E Stillman; Peter Cummings; Dorothy Patton; Thomas Easterling Journal: Am J Obstet Gynecol Date: 2013-08-29 Impact factor: 8.661
Authors: H Julkunen; T Jouhikainen; R Kaaja; M Leirisalo-Repo; E Stephansson; T Palosuo; K Teramo; C Friman Journal: Lupus Date: 1993-04 Impact factor: 2.911
Authors: Tiziana Cotechini; Maria Komisarenko; Arissa Sperou; Shannyn Macdonald-Goodfellow; Michael A Adams; Charles H Graham Journal: J Exp Med Date: 2014-01-06 Impact factor: 14.307
Authors: Mimi Y Kim; Jill P Buyon; Marta M Guerra; Sarosh Rana; Dongsheng Zhang; Carl A Laskin; Michelle Petri; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Joan T Merrill; Mary D Stephenson; Qi Gao; S Ananth Karumanchi; Jane E Salmon Journal: Am J Obstet Gynecol Date: 2015-09-29 Impact factor: 8.661
Authors: K D Kolstad; J A Mayo; L Chung; Y Chaichian; V M Kelly; M Druzin; D K Stevenson; G M Shaw; J F Simard Journal: BJOG Date: 2019-10-31 Impact factor: 6.531
Authors: Julia F Simard; Elizabeth V Arkema; Cathina Nguyen; Elisabet Svenungsson; Anna-Karin Wikström; Kristin Palmsten; Jane E Salmon Journal: Paediatr Perinat Epidemiol Date: 2016-12-12 Impact factor: 3.980